PMID- 23503128
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130319
LR  - 20220321
IS  - 2008-2010 (Print)
IS  - 2008-322X (Electronic)
IS  - 2008-322X (Linking)
VI  - 7
IP  - 4
DP  - 2012 Oct
TI  - Topical latanoprost does not cause macular thickening after uncomplicated 
      cataract surgery.
PG  - 289-94
AB  - PURPOSE: To explore changes in central macular thickness (CMT) after a two-month 
      period of glaucoma therapy with topical latanoprost after uneventful 
      phacoemulsification. METHODS: Forty-one eyes of 31 patients with primary open 
      angle or pseudoexfoliative glaucoma who required glaucoma medications after 
      cataract surgery were prospectively enrolled. All eyes had undergone uneventful 
      phacoemulsification with intraocular lens implantation at least 4 months before 
      initiation of latanoprost. After a complete ophthalmic examination, 
      spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography 
      (FA) were performed at baseline before starting latanoprost. All eyes received 
      latanoprost for 2 months, and clinical examinations were repeated one and two 
      months afterwards; OCT and FA were repeated after 2 months. Outcome measures were 
      CMT and loss of more than 2 lines of best corrected visual acuity (BCVA). 
      RESULTS: Mean patient age was 71.6+/-7.8 years. Intraocular pressure decreased from 
      21.5+/-3.4 mmHg to 14.4+/-2.6 mmHg (p<0.001) at 2 months. None of the eyes developed 
      reduction of BCVA exceeding 2 lines, or angiographic cystoid macular edema (CME). 
      Likewise no significant change was noted in CMT (249.9+/-29.8 vs 248.8+/-30.7microm), 
      average macular thickness (274.5+/-15.0 vs 273.8+/-17.0microm), or macular volume 
      (9.6+/-1.0 vs 9.6+/-1.1microm2) after treatment as compared to baseline (P>0.05 for all 
      comparisons). CONCLUSION: Topical use of latanoprost later than 4 months after 
      uncomplicated cataract surgery does not seem to predispose to increased macular 
      thickness or CME and may safely be used in this setting.
FAU - Moghimi, Sasan
AU  - Moghimi S
AD  - Farabi Eye Research Center, Department of Ophthalmology, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Zandian, Mehdi
AU  - Zandian M
FAU - Latifi, Golshan
AU  - Latifi G
FAU - Amini, Heydar
AU  - Amini H
FAU - Eslami, Yadollah
AU  - Eslami Y
FAU - Zarei, Reza
AU  - Zarei R
FAU - Fakhraie, Ghasem
AU  - Fakhraie G
FAU - Nouri-Mahdavi, Kouros
AU  - Nouri-Mahdavi K
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - J Ophthalmic Vis Res
JT  - Journal of ophthalmic & vision research
JID - 101497643
PMC - PMC3595585
OTO - NOTNLM
OT  - Cystoid Macular Edema
OT  - Latanoprost
OT  - Macular Thickness
EDAT- 2013/03/19 06:00
MHDA- 2013/03/19 06:01
PMCR- 2012/10/01
CRDT- 2013/03/19 06:00
PHST- 2012/03/16 00:00 [received]
PHST- 2012/06/25 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/03/19 06:01 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - JOVR-07-289 [pii]
PST - ppublish
SO  - J Ophthalmic Vis Res. 2012 Oct;7(4):289-94.